Significance of combined determination of serum HE4, CA125 level and T lymphocyte subgroups in peripheral blood in early diagnosis of ovarian cancer

Chinese Journal of Biologicals

Volumn 25, Issue 1, 2012, Pages 99-101

  Li, Kai ^a   Yu, Yang ^b   He, Li Zhen ^b   Zhang, Jia Jia ^b   Li, Nan ^b  

^a Second People's Hospital of Jiaozuo City   (China)

^b NONE

Author keywords

CA125; HE4; Ovarian tumor; T lymphocyte subgroup

Indexed keywords

CA 125 ANTIGEN; MEMBRANE PROTEIN; PROTEIN HE4; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EARLY DIAGNOSIS; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

EID: 84863272337     PISSN: 10045503     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer[J]. Int J Gynaecol Obstet, 2006, 95 (Suppl1): S247-S257.
2. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer[J]. Mol Cell Proteomics, 2004, 3(4): 355-366. (Pubitemid 38702089)
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin, 2007, 57(1): 43-66.
4. Burges A, Schmalfeldt B. Ovarian cancer: diagnosis and treatment[J]. Dtsch Arztebl Int, 2011, 108 (38): 635-641.
5. Bast RC Jr, Badgwell D, Lu Z, et al. New tumour markers: CA 125 and beyond[J]. Int J Gynecol Cancer, 2005, 15(Suppl 3): 274-281. (Pubitemid 43096594)
6. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumour Markers guidelines for clinical use[J]. Int J Gynecol Cancer, 2005, 15(5): 679-691. (Pubitemid 41783071)
7. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008, 108(2): 402-408. (Pubitemid 351174295)
8. Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus[J]. Gynecol Oncol, 2008, 110(2): 196-201.